Bumper crop of new drugs fails to lift big pharma R&D returns

LONDON (Reuters) - It is shaping up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down.

Bumper crop of new drugs fails to lift big pharma R&D returns
Read More


Bagikan Berita Ini